Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Jonggi Choi"'
Autor:
Kyung Hwa Lee, Gwang Hyeon Choi, Jihye Yun, Jonggi Choi, Myung Ji Goh, Dong Hyun Sinn, Young Joo Jin, Minseok Albert Kim, Su Jong Yu, Sangmi Jang, Soon Kyu Lee, Jeong Won Jang, Jae Seung Lee, Do Young Kim, Young Youn Cho, Hyung Joon Kim, Sehwa Kim, Ji Hoon Kim, Namkug Kim, Kang Mo Kim
Publikováno v:
npj Digital Medicine, Vol 7, Iss 1, Pp 1-8 (2024)
Abstract The treatment decisions for patients with hepatocellular carcinoma are determined by a wide range of factors, and there is a significant difference between the recommendations of widely used staging systems and the actual initial treatment c
Externí odkaz:
https://doaj.org/article/db78a9799bd04ddca825268850366cd4
Autor:
Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Publikováno v:
Gut and Liver, Vol 18, Iss 1, Pp 147-155 (2024)
Background/Aims: With the wide application of direct-acting antivirals (DAAs) for hepatitis C virus infection, the number of patients achieving a sustained virologic response (SVR) will continue to increase. However, no consensus has been achieved on
Externí odkaz:
https://doaj.org/article/0af79f380fa44c0a8121bfe0fa40205f
Autor:
Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss 1, Pp 49-63 (2024)
Background/Aims Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect. Therefore, concerns have been raised as to whether these differences a
Externí odkaz:
https://doaj.org/article/d76e56c964ad4ba1b72800a944befeeb
Autor:
Hyeyeon Hong, Jonggi Choi
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss 2, Pp 272-273 (2024)
Externí odkaz:
https://doaj.org/article/339fe98edb184d1ba0adbd3bf82f2cad
Autor:
Jiwon Yang, Jonggi Choi
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss 2, Pp 164-165 (2024)
Externí odkaz:
https://doaj.org/article/3db0c433ca9d4144aefb95b7e31ccb93
Autor:
Sujin Jin, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jinhong Jung, Sang Min Yoon, Jonggi Choi
Publikováno v:
Journal of Liver Cancer, Vol 23, Iss 1, Pp 177-188 (2023)
Background/Aim The Barcelona Clinic Liver Cancer (BCLC) guidelines recommend systemic therapy as the only first-line treatment for patients with BCLC stage C hepatocellular carcinoma (HCC) despite its heterogeneity of disease extent. We aimed to iden
Externí odkaz:
https://doaj.org/article/53ea0306484a42b1b1f5e8d745c96b0e
Autor:
Dongsub Jeon, Hye Ryeong Cha, Sung Won Chung, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Seung Won Lee, Won-Mook Choi
Publikováno v:
EClinicalMedicine, Vol 65, Iss , Pp 102300- (2023)
Summary: Background: The majority of patients with hepatocellular carcinoma (HCC) following hepatic resection experience tumor recurrence. Statin use is associated with a reduced risk of HCC development; however, the association between statin use an
Externí odkaz:
https://doaj.org/article/aa44651b2dbf4da6b860df3d8135fec2
Autor:
Jonggi Choi, Jina Park, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung
Publikováno v:
Gut and Liver, Vol 16, Iss 6, Pp 964-975 (2022)
Background/Aims: The care cascade for hepatitis C virus (HCV) infection is impeded by multiple barriers, including suboptimal anti-HCV testing, link to care, and diagnosis. We explored the changes in the care cascade of HCV for the past 20 years and
Externí odkaz:
https://doaj.org/article/91333551f39a437da0228ea3f134f9e2
Autor:
Soo Min Ahn, Jonggi Choi, Byong Duk Ye, Suk-Kyun Yang, Ji Seon Oh, Yong‑Gil Kim, Chang-Keun Lee, Bin Yoo, Sang Hyoung Park, Seokchan Hong
Publikováno v:
Gut and Liver, Vol 16, Iss 4, Pp 567-574 (2022)
Background/Aims: Anti-hepatitis B virus (HBV) therapy is required for patients with HBV infection receiving biologics because of the high risk of HBV reactivation. However, it is unclear when to start biologics after anti-HBV treatment. We investigat
Externí odkaz:
https://doaj.org/article/69def27738bd49578475b0ef6262bd89
Autor:
Jihye Lim, Seungbong Han, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Dong Hwan Jung, Sung‐Gyu Lee, Ki‐Hun Kim, Jonggi Choi
Publikováno v:
Hepatology Communications, Vol 6, Iss 7, Pp 1689-1698 (2022)
Abstract Selecting an optimal donor for living donor liver transplantation is crucial for the safety of both the donor and recipient, and hepatic steatosis is an important consideration. We aimed to build a prediction model with noninvasive variables
Externí odkaz:
https://doaj.org/article/ffe00f853b70486c89b8c9766b516114